The VICI-DISEASE Consortium
The VICI-DISEASE consortium’s main objective is to exploit a phase-III validated capsid Virus Like Particle (cVLP) vaccine platform to develop a vaccine candidate portfolio and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for further development (Phase 2&3) in case of pandemic outbreaks.
The primary candidate will be Nipah virus (NiV), a high-mortality viral disease with no vaccines or treatments. We address the call topic by improving pandemic preparedness and response through development of a NiV vaccine to Ph1/2 and two filovirus vaccines to pre-clinical proof-of-concept.
Project title: Protection from viruses with epidemic and pandemic disease outbreak potential through development and clinical testing of a novel capsid virus like particle (CVLP) vaccine.
Acronym: VICI-DISEASE
Aim: To develop a Nipah virus (NiV) vaccine candidate based on a capsid virus-like particle platform.
Period: 01-12-2023 to 30-11-2027
Partners: University of Copenhagen, AdaptVac,
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (RADBOUDUMC), FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI), EXPRES2ION BIOTECHNOLOGIES, UNIVERSITAET LEIPZIG (ULEI).
Funder: the European Union
Total grant: 8 million Euro
July 2026:
- Vaccine candidate selected for the Nipah vaccine: using the Nipah G head combined to the cVLP using the tag/catcher system.
- GMP manufacturing of the Drug substance in progress.
- Challenge studies for the vaccine candidate will be carried out in hamsters and ferrets, using a Nipah virus challenge.
- Toxicity studies will be started in Q4 of 2026 and Ph1/2a clinical trial should be started in Q1 2027.
Read more here.
Professor Adam F. Sander Bertelsen
Email